| pubmed-article:7390386 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C0680536 | lld:lifeskim |
| pubmed-article:7390386 | lifeskim:mentions | umls-concept:C0125933 | lld:lifeskim |
| pubmed-article:7390386 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:7390386 | pubmed:dateCreated | 1980-9-23 | lld:pubmed |
| pubmed-article:7390386 | pubmed:abstractText | A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid). After randomization this pre-treatment was followed by a further 8 week-treatment with the comparison product (group I = 49 patients) or by a change-over to Lipo-Merz retard (group II = 49 patients). Lipo-Merz retard was administered in a dosage of one capsule/day, the combination product in a dosage of one capsule three times daily. In group I the serum cholesterol and serum triglyceride values achieved by the pre-treatment could be lowered by an average of 4%. In group II the reductions were 4% and 6%, respectively. Toleration was good in both groups. | lld:pubmed |
| pubmed-article:7390386 | pubmed:language | ger | lld:pubmed |
| pubmed-article:7390386 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7390386 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7390386 | pubmed:month | May | lld:pubmed |
| pubmed-article:7390386 | pubmed:issn | 0015-8178 | lld:pubmed |
| pubmed-article:7390386 | pubmed:author | pubmed-author:StegerWW | lld:pubmed |
| pubmed-article:7390386 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7390386 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7390386 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:7390386 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7390386 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7390386 | pubmed:pagination | (718-20) | lld:pubmed |
| pubmed-article:7390386 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:meshHeading | pubmed-meshheading:7390386-... | lld:pubmed |
| pubmed-article:7390386 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7390386 | pubmed:articleTitle | [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. | lld:pubmed |
| pubmed-article:7390386 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7390386 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7390386 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7390386 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:7390386 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
